Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00852189 · ClinicalTrials.gov registry record · Phase 1
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase 1 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT00852189: Completed Phase 1 study, sponsored by Endocyte.
NCT00852189 is a Phase 1 study that has completed, run by Endocyte. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00852189, a Phase 1 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0489 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
Interventions
- DRUG EC0489, Injection
- DRUG EC20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00852189
The ClinicalTrials.gov registry entry for NCT00852189 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EC0489, Injection is the first listed.
NCT00852189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00852189 about?
NCT00852189 is a clinical study titled "Study of EC0489 for the Treatment of Refractory or Metastatic Tumors". This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0489 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
What is the current status of trial NCT00852189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2009-04. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00852189?
The interventions under investigation include: EC0489, Injection (DRUG), EC20 (DRUG).
Who is sponsoring clinical trial NCT00852189?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.